Pharmacogenetics of EGFR and VEGP inhibition

被引：40

作者：

Pander, Jan ^{[1
]}

Gelderblom, Hans ^{[2
]}

Guchelaar, Henk-Jan ^{[1
]}

机构：

[1] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, NL-2300 RC Leiden, Netherlands

[2] Leiden Univ, Med Ctr, Dept Clin Oncol, NL-2300 RC Leiden, Netherlands

来源：

DRUG DISCOVERY TODAY | 2007年 / 12卷 / 23-24期

关键词：

D O I：

10.1016/j.drudis.2007.10.016

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Even though treatment of several types of solid tumours has improved in the past few years with the introduction of the monoclonal antibodies against epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF), response rates to these targeted therapies are modest. Pharmacogenetic factors have the potential to select patients with higher chance of response to agents that target these pathways. This review provides an overview over germ-line variations in genes that are potentially involved in the pharmacodynamics of the monoclonal antibodies cetuximab, panitumumab and bevacizumab, and which may underlie variable anti-tumour response.

引用

页码：1054 / 1060

页数：7

共 66 条

[1] An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors [J].

Amador, ML ;

Oppenheimer, D ;

Perea, S ;

Maitra, A ;

Cusati, G ;

Iacobuzio-Donahue, C ;

Baker, SD ;

Ashfaq, R ;

Takimoto, C ;

Forastiere, A ;

Hidalgo, M .

CANCER RESEARCH, 2004, 64 (24) :9139-9143

[2] A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes [J].

Awata, T ;

Inoue, K ;

Kurihara, S ;

Ohkubo, T ;

Watanabe, M ;

Inukai, K ;

Inoue, I ;

Katayama, S .

DIABETES, 2002, 51 (05) :1635-1639

[3] A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease [J].

Bhowmick, DA ;

Zhuang, ZP ;

Wait, SD ;

Weil, RJ .

CANCER RESEARCH, 2004, 64 (04) :1220-1223

[4] Novel polymorphisms in the promoter and 5′ UTR regions of the human vascular endothelial growth factor gene [J].

Brogan, IJ ;

Khan, N ;

Isaac, K ;

Hutchinson, JA ;

Pravica, V ;

Hutchinson, IV .

HUMAN IMMUNOLOGY, 1999, 60 (12) :1245-1249

[5] Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the-765G → C COX-2 polymorphism [J].

Brosens, LAA ;

Iacobuzio-Donahue, CA ;

Keller, JJ ;

Hustinx, SR ;

Carvalho, R ;

Morsink, FH ;

Hylind, LM ;

Offerhaus, GJ ;

Giardiello, FM ;

Goggins, M .

CLINICAL CANCER RESEARCH, 2005, 11 (11) :4090-4096

[6] Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An eastern cooperative oncology group study [J].

Burtness, B ;

Goldwasser, MA ;

Flood, W ;

Mattar, B ;

Forastiere, AA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8646-8654

[7] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[8] A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke [J].

Cipollone, F ;

Toniato, E ;

Martinotti, S ;

Fazia, M ;

Iezzi, A ;

Cuccurullo, C ;

Pini, B ;

Ursi, S ;

Vitullo, G ;

Averna, M ;

Arca, M ;

Montali, A ;

Campagna, F ;

Ucchino, S ;

Spigonardo, F ;

Taddei, S ;

Virdis, A ;

Ciabattoni, G ;

Notarbartolo, A ;

Cuccurullo, F ;

Mezzetti, A .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (18) :2221-2228

[9] Rituximab-dependent cytotoxicity by natural killer cells:: Influence of FCGR3A polymorphism on the concentration-effect relationship [J].

Dall'Ozzo, S ;

Tartas, S ;

Paintaud, G ;

Cartron, G ;

Colombat, P ;

Bardos, P ;

Watier, H ;

Thibault, G .

CANCER RESEARCH, 2004, 64 (13) :4664-4669

[10] Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy [J].

Di Fiore, F. ;

Blanchard, F. ;

Charbonnier, F. ;

Le Pessot, F. ;

Lamy, A. ;

Galais, M. P. ;

Bastit, L. ;

Killian, A. ;

Sesboue, R. ;

Tuech, J. J. ;

Queuniet, A. M. ;

Paillot, B. ;

Sabourin, J. C. ;

Michot, F. ;

Michel, P. ;

Frebourg, T. .

BRITISH JOURNAL OF CANCER, 2007, 96 (08) :1166-1169

← 1 2 3 4 5 6 7 →